Business Wire

United Engine Corporation: Russian-French SaM146 engine surpasses 600,000 flight hours

21.6.2017 14:26:00 EEST | Business Wire | Press release

Share

The Russian-French SaM146 engine that powers Sukhoi Superjet 100 (SSJ100) airliners has logged over 620 thousand flight hours in operation. The SaM146 engine, produced within the 50/50 partnership between Safran and UEC, is successfully operated all around the world by well-known airlines such Russian Aeroflot, Mexican Interjet and Irish CityJet.

UEC and Safran, PowerJet mother companies, are both exhibiting SaM146 engines at their respective stands at Paris Air Show 2017 in Le Bourget (France).

SaM146 is an integrated power plant which includes the engine and the nacelle equipped by a thrust reverser. The deliveries of SaM146 and all the after-sales services are performed by PowerJet, a joint venture formed on the principles of equal representation by Safran Aircraft Engines and Russian UEC-Saturn (a part of the United Engine Corporation, UEC). UEC-Saturn is a developer and producer of the fan, the low-pressure compressor and the low-pressure turbine, and is also responsible for the final engine assembly and its testing. Safran Aircraft Engines is a developer and producer of the high-pressure compressor, the combustion chamber, the high-pressure turbine, the gearbox, the FADEC system. The French company also performs the overall integration of the power plant and is responsible for the final engine assembly and ground tests.

The leading engine of Yakutia Airline has reached 7,800 flight hours; the leading Interjet engine has surpassed 6,400 flight cycles.

Since starting revenue service in 2011, the SaM146 engine has demonstrated the exceptional performance in service, with an engine dispatch reliability of 99,9%. Such performance is based on Safran Aircraft Engines and UEC experience in commercial engines to develop the SaM146. Its optimised design improves performance and facilitates on wing maintenance to keep up with the best rate of availability.

SaM146-powered SSJ100 are currently used by 15 operators. Some of them are conducting very intensive operations in harsh environments

In order to build the world class after-sales support system, two spare part distribution centres are operating in Russia (Lytkarino) and France (Villaroche). Such localisation of the warehouses lets us to deliver spare parts practically anywhere around the world in 24 hours. Two training facilities for airlines' technical personnel also function there. The round the clock customer support centre and a web-portal are also in operation.

The SaM146 is offered in two versions which are developed and certified in accordance with the Russian and European requirements: 1S17 and 1S18 for SSJ100-95B, SSJ100-95LR and SSJ100 B100 planes, 1S17С and 1S18С for VIP-versions of SSJ100.

UEC (United Engine Corporation, a part of the Rostec State Corporation) is specialising in development, serial production, service and support of engines for military and civil aviation, space programmes and navy, as well as oil and gas industry and power generation.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

United Engine Corporation
Alexander Artyukhov
press@uecrus.com
Tel. +7 (499) 558-38-83

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BitGo MENA Launches Regulated Electronic Trading, Delivering Full Suite Trading Services to the Region8.6.2026 07:00:00 EEST | Press release

BitGo MENA FZE (“BitGo MENA”), a subsidiary of BitGo Holdings, Inc. (NYSE: BTGO) (“BitGo”), the digital asset infrastructure company, today announced the launch of electronic trading in the Middle East and North African (MENA). With this launch, clients can now access a comprehensive trading solution combining BitGo MENA’s established over-the-counter (OTC) trading offering with institutional-grade electronic execution, all operating under BitGo MENA’s Broker-Dealer license from Dubai’s Virtual Assets Regulatory Authority (VARA). The launch further expands BitGo MENA’s regulated product suite under VARA’s oversight, marking another step in the region’s continued buildout of institutional digital asset infrastructure amid growing demand for integrated execution and custody solutions. “The Middle East and North Africa has quickly become one of the most exciting regions in the world for digital assets, with regulators, institutions, and innovators moving with real purpose,” said Mike Bels

Vertex Presents New Data on ALYFTREK ® at European Cystic Fibrosis Conference5.6.2026 19:00:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data demonstrating the potentially transformative impact of treating cystic fibrosis (CF) with ALYFTREK ® (vanzacaftor/tezacaftor/deutivacaftor) in children ages 2 to 5, as well as data from 96-week interim analyses of two open-label extension studies of ALYFTREK in children 6 to 11 years and people 12 years and older demonstrating the long-term safety and efficacy profile of the medicine. The data, presented at the European Cystic Fibrosis Conference, show children ages 2 to 5 with vanzacaftor/tezacaftor/deutivacaftor-responsive genotypes including those who are homozygous for the F508del mutation (F/F) and those who have F508del/minimal function mutations (F/MF)on ALYFTREK had further improvement in CFTR function from a TRIKAFTA ® baseline as measured by sweat chloride (SwCl), with 65% having achieved SwCl <30 mmol/L after treatment with ALYFTREK. Vertex also presented Phase 3 data of children ages 1 to <2 with TRIKAF

Owkin to Build AI Agents as Part of a Multi-Year K Pro Collaboration with Sanofi5.6.2026 14:00:00 EEST | Press release

Owkin, the agentic AI company pioneering Biological Artificial Superintelligence to transform drug discovery and development, today announced a multi-year collaboration with Sanofi to co-develop next-generation biopharma agents, to be backed by a five-year license for K Pro, Owkin’s AI Scientist. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260605704506/en/ K Pro, Owkin's AI scientist for biology, powered by multimodal patient data for smarter biopharma decision making. Owkin and Sanofi have collaborated since 2021 through a €90 million strategic partnership focused on target identification in oncology and patient subgrouping. The collaboration was later expanded to include drug positioning for Sanofi’s immunology pipeline. This new collaboration represents the next evolution in the partnership. During the five-year collaboration, Owkin will lead the end-to-end development of novel AI-driven biopharma agents purpose-built

DFNS Rebrands as the Core Banking Platform for Digital Assets5.6.2026 13:41:00 EEST | Press release

DFNS today announced a rebrand, marking its evolution from a wallet infrastructure to the first core banking platform for digital assets. The company is introducing a new logo, website, and market position as fintechs and institutions move their products and operations onchain. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260603859127/en/ Banks, fintechs, asset managers, trading firms, payment providers, market infrastructures, and clearing houses have stopped asking how to "add crypto." They're asking how to run financial products, controls, workflows, and client services on blockchain rails, with the reliability expected of core infrastructure. Some are going further still, exploring whether the blockchain can serve as the ledger itself, where an account is an onchain object rather than a row in a database. Where IBANs, virtual accounts, and blockchain wallets converge into one governed financial account. “DFNS was built

Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.6.2026 13:30:00 EEST | Press release

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to seventeen newly hired non-executive employees. The equity awards were granted on June 1, 2026 and consisted of options to purchase an aggregate of 157,000 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 74,700 shares. The options have an exercise price per share equal to $14.19, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restrict

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye